The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature

George Zarkavelis; Davide Mauri; Fotini Karassa; Kampletsas Eleftherios; George Pentheroudakis; Alexandra Pappadaki; Leonidas Mavroeidis; Panagiotis Ntellas; Stefania Gkoura; Ioanna Gazouli

doi:10.5114/wo.2020.94727

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2020
vol. 24

Send email

Copy url:

abstract:

Case report

The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature

George Zarkavelis

¹

,

Davide Mauri

¹

,

Fotini Karassa

¹

,

Kampletsas Eleftherios

¹

,

George Pentheroudakis

¹

,

Alexandra Pappadaki

¹

,

Leonidas Mavroeidis

¹

,

Panagiotis Ntellas

¹

,

Stefania Gkoura

¹

,

Ioanna Gazouli

¹

Department of Medical Oncology, University Hospital of Ioannina, Greece

Contemp Oncol (Pozn) 2020; 24 (1): 75-78

DOI: https://doi.org/10.5114/wo.2020.94727

Online publish date: 2020/03/30

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Zarkavelis G, Mauri D, Karassa F, et al. The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature. Contemporary Oncology/Współczesna Onkologia. 2020;24(1):75-78. doi:10.5114/wo.2020.94727.

APA

Zarkavelis, G., Mauri, D., Karassa, F., Eleftherios, K., Pentheroudakis, G.,  & Pappadaki, A. et al. (2020). The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature. Contemporary Oncology/Współczesna Onkologia, 24(1), 75-78. https://doi.org/10.5114/wo.2020.94727

Chicago

Zarkavelis, George, Davide Mauri, Fotini Karassa, Kampletsas Eleftherios, George Pentheroudakis, Alexandra Pappadaki,  and Leonidas Mavroeidis et al. 2020. "The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature". Contemporary Oncology/Współczesna Onkologia 24 (1): 75-78. doi:10.5114/wo.2020.94727.

Harvard

Zarkavelis, G., Mauri, D., Karassa, F., Eleftherios, K., Pentheroudakis, G., Pappadaki, A., Mavroeidis, L., Ntellas, P., Gkoura, S.,  and Gazouli, I. (2020). The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature. Contemporary Oncology/Współczesna Onkologia, 24(1), pp.75-78. https://doi.org/10.5114/wo.2020.94727

MLA

Zarkavelis, George et al. "The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature." Contemporary Oncology/Współczesna Onkologia, vol. 24, no. 1, 2020, pp. 75-78. doi:10.5114/wo.2020.94727.

Vancouver

Zarkavelis G, Mauri D, Karassa F, Eleftherios K, Pentheroudakis G, Pappadaki A et al. The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature. Contemporary Oncology/Współczesna Onkologia. 2020;24(1):75-78. doi:10.5114/wo.2020.94727.

PlumX metrics:

With the advent of immunotherapy and with the expanding spectrum of malignancies treated with immunomodulatory agents, a new kind of adverse events has come under the spotlight. Clinicians have to be aware of immune-related adverse events and their clinical manifestations. Immunotherapy has been strongly associated with endocrinopathies, gastrointestinal, pulmonary, cutaneous, and renal toxicities but the incidence of rheumatologic adverse events is lower compared to the aforementioned systems. Dermatomyositis is an autoimmune myopathy which has been correlated to underlying evident or occult malignancies. Apart from its characteristic symptoms and signs, the presence of specific antibodies such as anti-transcriptional intermediary factor 1γ (anti-TIF 1γ) usually supports the diagnosis of paraneoplastic nature of the disease. However, a solid distinction between paraneoplastic syndrome and immune-related adverse event is still missing and remains to be elucidated. We here present a case of dermatomyositis in a male patient who underwent four cycles of combined ipilimumab and nivolumab immunotherapy. This is, to our knowledge, the first case of dermatomyositis following combined immune checkpoint inhibition therapy.

keywords:

The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature

George Zarkavelis 1 , Davide Mauri 1 , Fotini Karassa 1 , Kampletsas Eleftherios 1 , George Pentheroudakis 1 , Alexandra Pappadaki 1 , Leonidas Mavroeidis 1 , Panagiotis Ntellas 1 , Stefania Gkoura 1 , Ioanna Gazouli 1

urothelial cancer, dermatomyositis, immunotherapy, ipilimumab, nivolumab, anti-TIF-1γ, paraneoplastic, autoimmune

George Zarkavelis

¹

,

Davide Mauri

¹

,

Fotini Karassa

¹

,

Kampletsas Eleftherios

¹

,

George Pentheroudakis

¹

,

Alexandra Pappadaki

¹

,

Leonidas Mavroeidis

¹

,

Panagiotis Ntellas

¹

,

Stefania Gkoura

¹

,

Ioanna Gazouli

¹